New combo therapy aims to improve stem cell transplants for leukemia patients
NCT ID NCT00544466
First seen Feb 26, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This study tests a new conditioning regimen using a precise type of radiation (helical tomotherapy) along with two chemotherapy drugs (fludarabine and melphalan) before a donor stem cell transplant. The goal is to reduce side effects and improve outcomes for people with leukemia or myelodysplastic syndromes. The trial enrolled 75 participants and is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010-3000, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fludarabine phosphate, melphalan, and radiation therapy
What this could lead to
If successful, this approach could make stem cell transplants safer and more effective for people with blood cancers.
What could go wrong
This is an early-phase trial with only 75 participants, so results may not apply broadly. There are risks of serious side effects from the chemotherapy and radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.